الفهرس 
Acute Myeloid LeukemiaOnly 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
Background:: CD30, a member of (TNFR) superfamily, was originally identified as a cell-surface marker of Reed-Sternberg cell in classical Hodgkin Lymphoma, CD30 is also expressed by Several types of T- and B- cell non-Hodgkin’s Lymphoma, such as anaplastic large cell lymphoma (ALCL), primary mediastinal large B- cell lymphoma (PMBCL) and Epstein-Barr-Virus (EBV)- driven clonal lymphoproliferative disorder as well as in reactive conditions such as infectious mononucleosis.Patients and methods: A cross-sectional study that was conducted at Clinical Hematology Department in Ain Shams University Hospital during a period from Novomber 2016 to August 2017. 20 new cases of AML and ALL ,30 refractory / or relapsed cases of AML and ALL either T or B , enrolled in this study , CD30 % expression was assessed by flowcytometery on bone marrow sample or peripheral blood. Results: CD30 with cutoff >20% (+ve) was 46% of cases while cases with cutoff <20%(-ve) was 54% in all leukemia cases,CD30 expresssion was higher in ALL especially In T-ALL with mean value (44.564±27.158) with significant increase relapsed T-ALL (P value 0.031) followed by B-ALL (23.988±15.678). CD30 expression in relapsed AML and ALL showed an increased % but not yet statistically significant. Significant correlation was found in risk parameters as in WBCs (>100,000),PLT (<30,000) and CD30 expression in T ALL patients with P value 0.038and 0.021 respectively, and non significant between LDH and MRD in T-ALL and all risk parameters in B-ALL. ROC curve revealed that the accuracy of sensitivity and specificity was 69.9%. Conclusion: CD30 has been shown to be a significant diagnostic tool in cases of acute leukemia especially in newly and relapsed TALL, also it can be labeled to be targeted therapy, Drug trial using monoclonal AB to CD30 as treatment in relapsed /refractory cases with special concern to response and survival rate